In this weeks VJOncology podcast, three oncology experts delve into the transformative potential of liquid biopsy in breast cancer treatment.
First, Michail Ignatiadis (Jules Bordet Institute, Brussels, Belgium) discusses the clinical applications and challenges of utilizing liquid biopsy in metastatic breast cancer, focusing on the Phase III TREAT ctDNA trial (NCT05512364) and its implications for ER-positive, HER2-negative cases. Next, Marina Sharifi (University of Wisconsin Carbone Cancer Center, Madison, WI) introduces an innovative fragmentomic analysis of circulating tumor DNA (CT-DNA) to discern estrogen receptor status in metastatic breast cancer, potentially minimizing the need for invasive tissue biopsies. Finally, Guilherme Nader-Marta (Dana-Farber Cancer Center, Boston, MA) shares insights from the PACE trial (NCT03147287), highlighting two pivotal studies that explore biomarkers in ER-positive, HER2-negative metastatic breast cancer and underscore the prognostic value of liquid biopsy in optimizing treatment strategies.
For more updates on breast cancer, be sure to visit our dedicated Breast Cancer Channel.
